Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
KAT6A-IN-1
CAS:<p>KAT6A-IN-1 (compound 5) is an inhibitor of KAT6A.</p>Fórmula:C23H27N5O5SCor e Forma:SolidPeso molecular:485.56HLCL-61
CAS:<p>HLCL-61 is a premier small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5).</p>Fórmula:C23H24N2OCor e Forma:SolidPeso molecular:344.45LSD1-IN-16
<p>LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43Bromodomain inhibitor-13
CAS:<p>Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.</p>Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.43CP-352664
CAS:<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Fórmula:C18H18N4Cor e Forma:SolidPeso molecular:290.36SMARCA2-IN-2
CAS:<p>Compound I-25, also known as SMARCA2-IN-2, is a SMARCA2 inhibitor (IC 50: 101-500 μM) with applications in cancer research.</p>Fórmula:C16H17N3Cor e Forma:SolidPeso molecular:251.33AJI-100
CAS:<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Fórmula:C17H14FN5OCor e Forma:SolidPeso molecular:323.32PFI-6-COOH
CAS:<p>PFI-6-COOH (Compound 18) is a ligand for the eleven-nineteen leukemia (ENL) protein, and is utilized in the synthesis of the ENL PROTAC degrader MS41.</p>Fórmula:C23H21N3O6Cor e Forma:SolidPeso molecular:435.43NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Fórmula:C22H28N2O3Cor e Forma:SolidPeso molecular:368.47cis-4-Br-2,5-F2-PCPA
<p>cis-4-Br-2,5-F2-PCPA (S1024) blocks LSD1/LSD2 (Ki: 94 nM/8.4 μM), hinders cancer stem cell growth, raises H3K4me2 in CCRF-CEM cells.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07YLIU-4-105-1
CAS:<p>YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.</p>Fórmula:C32H34F3N7O2Cor e Forma:SolidPeso molecular:605.65Cenacitinib
CAS:<p>Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.</p>Fórmula:C19H19F2N7O3Cor e Forma:SolidPeso molecular:431.40CBP/p300-IN-2
CAS:<p>CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).</p>Fórmula:C27H29F2N7O2Pureza:98%Cor e Forma:SolidPeso molecular:521.56PRMT5-IN-1
CAS:<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Fórmula:C19H19ClN4O5Pureza:98%Cor e Forma:SolidPeso molecular:418.83PARP1/2-IN-4
CAS:<p>PARP1/2-IN-4 (compound 3) is an inhibitor of PARP1/2.</p>Fórmula:C23H30FN5O6Cor e Forma:SolidPeso molecular:491.51LSD1/HDAC-IN-1
CAS:<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C18H18N2O4SCor e Forma:SolidPeso molecular:358.41DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Fórmula:C15H8Cl2O3Cor e Forma:SolidPeso molecular:307.128SCR-7952
CAS:<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Fórmula:C19H15ClN4OCor e Forma:SolidPeso molecular:350.80XP-524
CAS:<p>XP-524: BET & EP300 inhibitor, suppresses KRAS tumors in vivo, targets PDAC, boosts immune response.</p>Fórmula:C30H28N6O3SCor e Forma:SolidPeso molecular:552.65PARP14 inhibitor 2
CAS:<p>PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.</p>Fórmula:C25H32FN3O4SCor e Forma:SolidPeso molecular:489.60MS8815
CAS:<p>MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.</p>Fórmula:C65H87N9O8SCor e Forma:SolidPeso molecular:1154.51PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Cor e Forma:SolidPeso molecular:566.63BET-IN-6
CAS:<p>BET-IN-6: Potent BRD2/4 inhibitor and ligand for PROTAC BRD2/BRD4 degrader-1 synthesis.</p>Fórmula:C22H20N2O6SPureza:98%Cor e Forma:SolidPeso molecular:440.47PRMT5-IN-19
<p>PRMT5-IN-19 is a potent, selective PRMT5 inhibitor with IC50 of 23.9 nM and 47 nM, showing anti-cancer activity by inducing apoptosis.</p>Fórmula:C25H24N4OCor e Forma:SolidPeso molecular:396.48Itareparib
CAS:<p>Itareparib is a PARP inhibitor with demonstrated antitumor activity.</p>Fórmula:C20H26FN3O2Cor e Forma:SolidPeso molecular:359.438HIF-1α-IN-4
<p>HIF-1α-IN-4 is an inhibitor of HIF-1α with IC50 of 24 nM in HEK293T cells which has potential antitumor effects.</p>Fórmula:C16H12N2O3Cor e Forma:SolidPeso molecular:280.28HIF-2α-IN-7
CAS:<p>HIF-2α-IN-7 is a hypoxia inducible factor 2α (HIF-2α) inhibitor.</p>Fórmula:C18H9F6NO2Cor e Forma:SolidPeso molecular:385.26TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Cor e Forma:SolidPeso molecular:489.458(1-Nitroethene-1,2-diyl)dibenzene
CAS:<p>(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.</p>Fórmula:C14H11NO2Cor e Forma:SolidPeso molecular:225.24Trichostatin A S-isomer
CAS:<p>Trichostatin A S-isomer, a HDAC 1, 3, 4, 6, 10 inhibitor with IC50 ~20 nM, has wide-ranging epigenetic effects.</p>Fórmula:C17H22N2O3Pureza:98%Cor e Forma:SolidPeso molecular:302.37OM-153
CAS:<p>OM-153 blocks tankyrase 1 (IC50: 13 nM) and 2 (IC50: 2 nM), stifling WNT signaling and COLO 320DM cell growth.</p>Fórmula:C28H24FN7O2Cor e Forma:SolidPeso molecular:509.53CM-414
CAS:<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Fórmula:C23H29N5O4Pureza:98%Cor e Forma:SolidPeso molecular:439.51RL5a
CAS:<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Fórmula:C17H19N3OCor e Forma:SolidPeso molecular:281.35Ten01
<p>Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.</p>Fórmula:C18H20F6N4OCor e Forma:SolidPeso molecular:422.37HDAC-IN-47
<p>HDAC-IN-47: Oral HDAC inhibitor (IC50: 19.75-302.73 nM for HDAC1-8), blocks G2/M, inhibits autophagy, triggers apoptosis, anti-cancer in vivo.</p>Fórmula:C17H20BrN3O4Cor e Forma:SolidPeso molecular:410.26JAK-IN-23
<p>"JAK-IN-23: oral dual JAK/STAT & NF-κB inhibitor; JAK1 (IC50: 8.9 nM), JAK2 (15 nM), JAK3 (46.2 nM); for IBD research."</p>Fórmula:C23H22Cl2N4OCor e Forma:SolidPeso molecular:441.35HDAC8-IN-2
<p>HDAC8-IN-2 (5o) inhibits both smHDAC8 and hHDAC8 with IC50s of 0.27 μM, 0.32 μM, kills schistosome larvae, and lowers egg laying.</p>Fórmula:C21H16N2O5Cor e Forma:SolidPeso molecular:376.36Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Fórmula:C33H43FN6O3Cor e Forma:SolidPeso molecular:590.73MI-1481
CAS:<p>MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.</p>Fórmula:C29H30F3N7O2SPureza:98%Cor e Forma:SolidPeso molecular:597.65HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Fórmula:C26H22N4O2Cor e Forma:SolidPeso molecular:422.48WW437
<p>WW437 is a histone deacetylase (HDAC) inhibitor that exhibits potent anti-breast cancer activity both in vitro and in vivo.</p>Fórmula:C23H27N5O4Cor e Forma:SolidPeso molecular:437.49MMSET-IN-1
CAS:<p>MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .</p>Fórmula:C18H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:423.47Equisetin
CAS:<p>Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.</p>Fórmula:C22H31NO4Pureza:98%Cor e Forma:SolidPeso molecular:373.49PAD4-IN-5
CAS:<p>PAD4-IN-5 (Example 18) is a PAD4 inhibitor with an IC50 of ≤10 nM at 50 µM Ca2+ and 101-500 nM at 1 mM Ca2+ against human PAD4 (hPAD4). This compound is applicable in the study of autoimmune diseases such as rheumatoid arthritis (RA).</p>Fórmula:C34H41N7O3Cor e Forma:SolidPeso molecular:595.734LSD1-IN-18
<p>LSD1-IN-18 inhibits LSD1 (Ki: 0.156 μM, KD: 0.075 μM), blocking THP-1 and MDA-MB-231 cell growth (IC50: 0.16, 0.21 μM).</p>Fórmula:C31H40N6O2Cor e Forma:SolidPeso molecular:528.69(2S,3R)-LP99
CAS:<p>(2S,3R)-LP99 is a less active enantiomer of LP99.</p>Fórmula:C26H30ClN3O4SPureza:98%Cor e Forma:SolidPeso molecular:516.05HDAC-IN-32
<p>HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.</p>Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.41AFM-30a hydrochloride
<p>AFM-30a hydrochloride: selective PAD2 inhibitor, EC50 9.5 μM; blocks H3 guanylation, EC50 0.4 μM; used for cancer and autoimmune research.</p>Fórmula:C24H28ClFN6O3Cor e Forma:SolidPeso molecular:502.97GSK3368715
CAS:<p>GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50s</p>Fórmula:C20H38N4O2Pureza:98%Cor e Forma:SolidPeso molecular:366.54FT001
CAS:<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Fórmula:C25H29N3O4SPureza:99.9%Cor e Forma:SolidPeso molecular:467.58
